Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and Stride, Inc. (NYSE: LRN): Grabar Law ...
Ibotta, Inc. Class A (IBTA)
Company Research
Source: GlobeNewswire
PHILADELPHIA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/cytokinetics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its officers made materially false and misleading statements on to the market, Specifically, on March 10, 2025, Cytokinetics discl
Show less
Read more
Impact Snapshot
Event Time:
IBTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBTA alerts
High impacting Ibotta, Inc. Class A news events
Weekly update
A roundup of the hottest topics
IBTA
News
- Ibotta (NYSE:IBTA) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Ibotta: A Non-Rewarding Experience [Seeking Alpha]Seeking Alpha
- Ibotta returns to downtown Denver with headquarters on 16th Street [CBS News]CBS News
- 5 Must-Read Analyst Questions From Ibotta's Q3 Earnings Call [Yahoo! Finance]Yahoo! Finance
- Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); enCore Energy Corp. (NASDAQ: EU); Fluor Corporation (NYSE: FLR); Fortrea Holdings, Inc. (NASDAQ: FTRE); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating ClaiGlobeNewswire
IBTA
Earnings
- 11/12/25 - Beat
IBTA
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IBTA's page on the SEC website